Published January 3, 2023
| Version v1
Report
Open
Health as a fundamental value. Towards an inclusive and equitable pharmaceutical strategy for the European Union
Description
Report produced by The EAHL Interest Group on Supranational Biolaw, and the 2021 Thematic Network on an inclusive and equitable Pharmaceutical Strategy, under the scientific coordination of Aurélie Mahalatchimy and Éloïse Gennet.
Files
EAHL IG BIOLAW - Inclusive Pharma Strategy - FINAL JOINT STATEMENT - 31.5.22.pdf
Additional details
Funding
- Agence Nationale de la Recherche
- I-BioLex - Fragmentation and defragmentation of the law on biomedical innovations ANR-20-CE26-0007